Bicycle Partners With Biogen Spinout Against Rare Blood Disorders
Executive Summary
Bicycle Therapeutics and Biogen spinoff Bioverativ have teamed up to develop novel treatments for hemophilia and sickle cell disease under a multi-million-dollar discovery and development agreement.
You may also be interested in...
Deal Watch: Genentech Sees Bicycle As Route To Novel Targeted Cancer Immunotherapies
Genentech pays $30m up front in a collaboration with Bicycle in a deal that could bring the UK biotech roughly $1.7bn in total. Also, deals involving Nimble, Seattle Genetics, Five Prime, Fresenius, Vifor, Yuhan, Imnewrun, Paratek, Almirall, MBD, AzothBio, Norgine, Faes, Aspen Pharmacare, Swixx.
IPO Update: Pace Of US Offerings Slows As 13 Biopharmas Go Public In 2019
With about three IPOs per month compared with a pace of nearly six per month in 2018, drug developers have raised $1.55bn with US offerings this year – though returns have been mixed.
Bioverativ: More Than Just A Hemophilia Company
The blood disease specialist, to be acquired by Sanofi, is best known for its two marketed hemophilia drugs, but Bioverativ spent 2017 working on business development and diversifying beyond hemophilia. Scrip talked to CEO John Cox about the pipeline just before the merger was announced.